Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

CCN6: a novel method of aTAKing cancer.

Leask A.

J Cell Commun Signal. 2013 Jun;7(2):161-2. doi: 10.1007/s12079-012-0189-8. Epub 2013 Jan 5.

2.

CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer.

Pal A, Huang W, Li X, Toy KA, Nikolovska-Coleska Z, Kleer CG.

Cancer Res. 2012 Sep 15;72(18):4818-28. doi: 10.1158/0008-5472.CAN-12-0154. Epub 2012 Jul 17.

3.

CCN6: a modulator of breast cancer progression.

Leask A.

J Cell Commun Signal. 2016 Jun;10(2):163-4. doi: 10.1007/s12079-016-0321-2. Epub 2016 Apr 16. Review.

4.

CCN6 (WISP3): a new anti-cancer therapy?

Leask A.

J Cell Commun Signal. 2010 Dec;4(4):199-200. doi: 10.1007/s12079-010-0106-y. Epub 2010 Nov 9.

5.

Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.

Huang W, Gonzalez ME, Toy KA, Banerjee M, Kleer CG.

Cancer Res. 2010 Apr 15;70(8):3340-50. doi: 10.1158/0008-5472.CAN-09-4225.

6.

The matricellular protein CCN6 (WISP3) decreases Notch1 and suppresses breast cancer initiating cells.

Huang W, Martin EE, Burman B, Gonzalez ME, Kleer CG.

Oncotarget. 2016 May 3;7(18):25180-93. doi: 10.18632/oncotarget.7734.

7.

MMTV-cre;Ccn6 knockout mice develop tumors recapitulating human metaplastic breast carcinomas.

Martin EE, Huang W, Anwar T, Arellano-Garcia C, Burman B, Guan JL, Gonzalez ME, Kleer CG.

Oncogene. 2017 Apr 20;36(16):2275-2285. doi: 10.1038/onc.2016.381. Epub 2016 Nov 7.

8.
9.

Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1.

Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, Kleer CG.

Am J Pathol. 2008 Apr;172(4):893-904. doi: 10.2353/ajpath.2008.070899. Epub 2008 Mar 5.

10.

CCN6 (WISP3) decreases ZEB1-mediated EMT and invasion by attenuation of IGF-1 receptor signaling in breast cancer.

Lorenzatti G, Huang W, Pal A, Cabanillas AM, Kleer CG.

J Cell Sci. 2011 May 15;124(Pt 10):1752-8. doi: 10.1242/jcs.084194. Epub 2011 Apr 26.

12.

CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer.

Kleer CG, Zhang Y, Merajver SD.

Cells Tissues Organs. 2007;185(1-3):95-9. Review.

PMID:
17587813
13.

On how CCN6 suppresses breast cancer growth and invasion.

Huang W, Pal A, Kleer CG.

J Cell Commun Signal. 2012 Mar;6(1):5-10. doi: 10.1007/s12079-011-0148-9. Epub 2011 Aug 13.

14.

Dual roles of CCN proteins in breast cancer progression.

Kleer CG.

J Cell Commun Signal. 2016 Sep;10(3):217-222. Epub 2016 Aug 12.

15.
16.

Activin A induction of murine and ovine follicle-stimulating hormone β transcription is SMAD-dependent and TAK1 (MAP3K7)/p38 MAPK-independent in gonadotrope-like cells.

Wang Y, Bernard DJ.

Cell Signal. 2012 Aug;24(8):1632-40. doi: 10.1016/j.cellsig.2012.04.006. Epub 2012 Apr 20.

PMID:
22549017
17.

TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival.

Gingery A, Bradley EW, Pederson L, Ruan M, Horwood NJ, Oursler MJ.

Exp Cell Res. 2008 Sep 10;314(15):2725-38. doi: 10.1016/j.yexcr.2008.06.006. Epub 2008 Jun 13.

18.

CCN6 as a profibrotic mediator that stimulates the proliferation of lung fibroblasts via the integrin β1/focal adhesion kinase pathway.

Batmunkh R, Nishioka Y, Aono Y, Azuma M, Kinoshita K, Kishi J, Makino H, Kishi M, Takezaki A, Sone S.

J Med Invest. 2011 Aug;58(3-4):188-96.

20.

The CCN family of genes: a perspective on CCN biology and therapeutic potential.

Yeger H, Perbal B.

J Cell Commun Signal. 2007 Dec;1(3-4):159-64. doi: 10.1007/s12079-008-0022-6. Epub 2008 Jun 21.

Supplemental Content

Support Center